Table 1.
Baseline characteristics of patients in matched subgroups by type of ICS use
| Permanent users | Use at baseline | |||||
|---|---|---|---|---|---|---|
| FP (n = 825) |
Other ICS (n = 825) |
No ICS (n = 825) |
FP (n = 1334) |
Other ICS (n = 1334) |
No ICS (n = 1334) |
|
| Male, n (%) | 570 (69.1) | 620 (75.2) | 624 (75.6) | 942 (70.6) | 1014 (76.0) | 996 (74.7) |
| Age, years, mean (SD) | 65.0 (8.0) | 64.9 (8.0) | 64.8 (7.8) | 64.9 (8.0) | 64.9 (7.9) | 64.8 (7.8) |
| Height, cm, mean (SD) | 169.81 (9.2) | 169.71 (8.6) | 170.30 (8.5) | 169.52 (9.0) | 169.79 (8.4) | 169.85 (8.7) |
| Weight, kg, mean (SD) | 77.82 (16.7) | 75.09 (15.9) | 76.08 (18.1) | 76.87 (16.7) | 75.41 (16.3) | 75.78 (17.9) |
| Body mass index, kg/m2, mean (SD) | 26.89 (5.0) | 25.97 (4.6) | 26.10 (5.3) | 26.65 (5.0) | 26.05 (4.8) | 26.15 (5.4) |
| Race, n (%) | ||||||
| White | 808 (97.9) | 808 (97.9) | 808 (97.9) | 1291 (96.8) | 1291 (96.8) | 1291 (96.8) |
| Black | – | – | – | 1 (0.1) | 1 (0.1) | 1 (0.1) |
| Asian | 17 (2.1) | 17 (2.1) | 17 (2.1) | 42 (3.1) | 42 (3.1) | 42 (3.1) |
| Current smoker, n (%) | 191 (23.2) | 216 (26.2) | 298 (36.1) | 316 (23.7) | 347 (26.0) | 473 (35.5) |
| Non-inhaled steroid use, n (%) | 83 (10.1) | 78 (9.5) | 52 (6.3) | 129 (9.7) | 114 (8.5) | 74 (5.5) |
| Anticholinergic use, n (%) | 422 (51.2) | 372 (45.1) | 308 (37.3) | 692 (51.9) | 637 (47.8) | 542 (40.6) |
| GOLD stage, n (%) | ||||||
| II | 395 (47.9) | 395 (47.9) | 395 (47.9) | 621 (46.6) | 621 (46.6) | 621 (46.6) |
| III | 371 (45.0) | 371 (45.0) | 371 (45.0) | 608 (45.6) | 608 (45.6) | 608 (45.6) |
| IV | 59 (7.2) | 59 (7.2) | 59 (7.2) | 105 (7.9) | 105 (7.9) | 105 (7.9) |
| FEV1, L, mean (SD) | 1.11 (0.4) | 1.12 (0.4) | 1.13 (0.4) | 1.09 (0.4) | 1.10 (0.4) | 1.10 (0.4) |
| FEV1, % predicted, mean (SD) | 39.72 (11.4) | 39.80 (11.5) | 39.78 (11.4) | 39.14 (11.5) | 39.10 (11.4) | 39.17 (11.4) |
| FVC, L, mean (SD) | 2.67 (0.9) | 2.70 (0.8) | 2.65 (0.8) | 2.63 (0.9) | 2.67 (0.8) | 2.62 (0.8) |
| FVC, % predicted, mean (SD) | 76.20 (18.6) | 75.88 (17.4) | 73.65 (17.0) | 74.99 (18.2) | 74.91 (17.5) | 73.68 (17.4) |
| FEV1/FVC, mean (SD) | 0.42 (0.1) | 0.42 (0.1) | 0.43 (0.1) | 0.42 (0.1) | 0.42 (0.1) | 0.43 (0.1) |
| Post-bronchodilator FEV1, L, mean (SD) | 1.34 (0.4) | 1.35 (0.4) | 1.37 (0.4) | 1.32 (0.4) | 1.33 (0.4) | 1.34 (0.4) |
| Post-bronchodilator FEV1, % predicted, mean (SD) | 48.06 (12.1) | 47.90 (12.1) | 48.09 (12.0) | 47.62 (12.3) | 47.30 (12.3) | 47.68 (12.4) |
Abbreviations: FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, SD standard deviation. Patients within each group were matched by race, age (± 5 years), FEV1% predicted (± 5% predicted), GOLD stage, emphysema diagnosis, and courses of antibiotics during the previous year